*PRIME® has identified, verified and mitigated any relevant financial relationships disclosed by speakers, authors, instructors, planners, peer reviewers or relevant staff prior to conducting an educational activity.
The following individuals have identified relevant financial relationships with companies that are not appropriate for disclosure:
- Ajai Chari, MD (Speaker)
Advisory board or committee – Adaptable, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Sanofi Genzyme
Advisor – AbbVie, Adaptable, Amgen, Antenna genes, Bristol-Myers Squibb, FORUMS, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Sanofi Genzyme, Takeda
Scholarships / Research funding – JanssenThe relationships reported above relate to the following therapeutic area: Hematology-Oncology
- Sarah Hammond, MD (Speaker)
Advisory board or committee – Melinta, Pfizer, Roche, Seres Therapeutics
Advisor – Pfizer
Scholarships / Research funding – Cider, F2G, GlaxoSmithKline, ScynexisThe relationships reported above refer to the following therapeutic area: Infectious diseases
The following persons have no relevant financial relationships with companies for which they are not eligible for disclosure:
- Joyce M Knestrick, PhD, CRNP, FAANP (Expert)
- Brad Boyette, MBA, MPA, PA-C (Planner)
- Ricardo Correa, MD, EdD, FACP, FACE, FAPCR, FACMQ (Planner)
None of the PRIME® employees involved in planning and content development have relevant financial relationships with companies that are not required to be disclosed.
